Anticancer Drugs Oncology Pharmacology Physiotherapy Ravulizumab-cwvz

Ravulizumab-cwvz (Mechanism of Action)

In this article we will discuss Ravulizumab-cwvz (Mechanism of Action)

In this article, we will discuss Ravulizumab-cwvz (Mechanism of Action). So, let’s get started.

Mechanism of Action

Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the terminal complement complex [C5b-9]) and preventing the generation of the terminal complement complex C5b9. Ravulizumab-cwvz inhibits terminal complement-mediated intravascular hemolysis in patients with PNH.


Immediate and complete inhibition of serum free C5 (concentration of less than 0.5
mcg/mL) was observed by the end of the first Ravulizumab-cwvz infusion and sustained throughout the entire 26-week treatment period in all patients, both complement-inhibitor naïve and previously treated with eculizumab.

The extent and duration of the pharmacodynamic response in patients with PNH were exposure dependent for Ravulizumab-cwvz. Free C5 levels of <0.5 mcg/mL were correlated with maximal intravascular hemolysis control and complete terminal complement inhibition.

Complete terminal complement inhibition following initiation of Ravulizumab-cwvz treatment led to normalization of serum LDH by week 4 in complement-inhibitor patients, and maintained LDH normalization in patients previously treated with eculizumab.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.